Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Gavreto (pralsetinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Allist, CStone Pharma, Rigel, Sanofi

Drug class:

RET inhibitor

Related drugs:

RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Oncocytic Carcinoma	RET fusion	Thyroid Gland Oncocytic Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Follicular Carcinoma	RET fusion	Thyroid Gland Follicular Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Anaplastic Carcinoma	RET fusion	Thyroid Gland Anaplastic Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Biliary Tract Cancer	RET fusion	Biliary Tract Cancer	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Pancreatic Cancer	RET fusion	Pancreatic Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Cholangiocarcinoma	RET fusion	Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Pancreatic Adenocarcinoma	RET fusion	Pancreatic Adenocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1